Lessons for pharmacogenomics studies: Association study between CYP2D6 genotype and tamoxifen response

Kazuma Kiyotani, Taisei Mushiroda, Naoya Hosono, Tatsuhiko Tsunoda, Michiaki Kubo, Fuminori Aki, Yutaka Okazaki, Koichi Hirata, Yuichi Takatsuka, Minoru Okazaki, Shozo Ohsumi, Takashi Yamakawa, Mitsunori Sasa, Yusuke Nakamura, Hitoshi Zembutsu

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

We earlier reported a significant association between the cytochrome P450 2D6 (CYP2D6) genotype and the clinical outcome in 282 Japanese breast cancer patients receiving tamoxifen monotherapy. Although many research groups have provided evidence indicating the CYP2D6 genotype as one of the strongest predictors of tamoxifen response, the results still remain controversial. We hypothesized that concomitant treatment was one of the causes of these controversial results. We then studied 167 breast cancer patients who received tamoxifen-combined therapy to evaluate the effects of concomitant treatment on the association analysis and observed no significant association between CYP2D6 genotype and recurrence-free survival (P=0.44, hazard ratio: 0.64, 95% confidential interval: 0.20-1.99 in patients with two variant alleles vs. patients without a variant allele). When we carried out two subgroup analyses for nodal status and tumor size, we observed a positive association between the CYP2D6 genotype and the clinical outcome only in patients who received tamoxifen monotherapy. This study explained a part of the discrepancies among the reported results.

Original languageEnglish
Pages (from-to)565-568
Number of pages4
JournalPharmacogenetics and genomics
Volume20
Issue number9
DOIs
Publication statusPublished - 01-09-2010

Fingerprint

Cytochrome P-450 CYP2D6
Tamoxifen
Genotype
Alleles
Breast Neoplasms
Therapeutics
Pharmacogenomic Testing
Recurrence
Survival
Research
Neoplasms

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Kiyotani, Kazuma ; Mushiroda, Taisei ; Hosono, Naoya ; Tsunoda, Tatsuhiko ; Kubo, Michiaki ; Aki, Fuminori ; Okazaki, Yutaka ; Hirata, Koichi ; Takatsuka, Yuichi ; Okazaki, Minoru ; Ohsumi, Shozo ; Yamakawa, Takashi ; Sasa, Mitsunori ; Nakamura, Yusuke ; Zembutsu, Hitoshi. / Lessons for pharmacogenomics studies : Association study between CYP2D6 genotype and tamoxifen response. In: Pharmacogenetics and genomics. 2010 ; Vol. 20, No. 9. pp. 565-568.
@article{3d585ced802043cc88f34d7e7bf1637d,
title = "Lessons for pharmacogenomics studies: Association study between CYP2D6 genotype and tamoxifen response",
abstract = "We earlier reported a significant association between the cytochrome P450 2D6 (CYP2D6) genotype and the clinical outcome in 282 Japanese breast cancer patients receiving tamoxifen monotherapy. Although many research groups have provided evidence indicating the CYP2D6 genotype as one of the strongest predictors of tamoxifen response, the results still remain controversial. We hypothesized that concomitant treatment was one of the causes of these controversial results. We then studied 167 breast cancer patients who received tamoxifen-combined therapy to evaluate the effects of concomitant treatment on the association analysis and observed no significant association between CYP2D6 genotype and recurrence-free survival (P=0.44, hazard ratio: 0.64, 95{\%} confidential interval: 0.20-1.99 in patients with two variant alleles vs. patients without a variant allele). When we carried out two subgroup analyses for nodal status and tumor size, we observed a positive association between the CYP2D6 genotype and the clinical outcome only in patients who received tamoxifen monotherapy. This study explained a part of the discrepancies among the reported results.",
author = "Kazuma Kiyotani and Taisei Mushiroda and Naoya Hosono and Tatsuhiko Tsunoda and Michiaki Kubo and Fuminori Aki and Yutaka Okazaki and Koichi Hirata and Yuichi Takatsuka and Minoru Okazaki and Shozo Ohsumi and Takashi Yamakawa and Mitsunori Sasa and Yusuke Nakamura and Hitoshi Zembutsu",
year = "2010",
month = "9",
day = "1",
doi = "10.1097/FPC.0b013e32833af231",
language = "English",
volume = "20",
pages = "565--568",
journal = "Pharmacogenetics and Genomics",
issn = "1744-6872",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

Kiyotani, K, Mushiroda, T, Hosono, N, Tsunoda, T, Kubo, M, Aki, F, Okazaki, Y, Hirata, K, Takatsuka, Y, Okazaki, M, Ohsumi, S, Yamakawa, T, Sasa, M, Nakamura, Y & Zembutsu, H 2010, 'Lessons for pharmacogenomics studies: Association study between CYP2D6 genotype and tamoxifen response', Pharmacogenetics and genomics, vol. 20, no. 9, pp. 565-568. https://doi.org/10.1097/FPC.0b013e32833af231

Lessons for pharmacogenomics studies : Association study between CYP2D6 genotype and tamoxifen response. / Kiyotani, Kazuma; Mushiroda, Taisei; Hosono, Naoya; Tsunoda, Tatsuhiko; Kubo, Michiaki; Aki, Fuminori; Okazaki, Yutaka; Hirata, Koichi; Takatsuka, Yuichi; Okazaki, Minoru; Ohsumi, Shozo; Yamakawa, Takashi; Sasa, Mitsunori; Nakamura, Yusuke; Zembutsu, Hitoshi.

In: Pharmacogenetics and genomics, Vol. 20, No. 9, 01.09.2010, p. 565-568.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Lessons for pharmacogenomics studies

T2 - Association study between CYP2D6 genotype and tamoxifen response

AU - Kiyotani, Kazuma

AU - Mushiroda, Taisei

AU - Hosono, Naoya

AU - Tsunoda, Tatsuhiko

AU - Kubo, Michiaki

AU - Aki, Fuminori

AU - Okazaki, Yutaka

AU - Hirata, Koichi

AU - Takatsuka, Yuichi

AU - Okazaki, Minoru

AU - Ohsumi, Shozo

AU - Yamakawa, Takashi

AU - Sasa, Mitsunori

AU - Nakamura, Yusuke

AU - Zembutsu, Hitoshi

PY - 2010/9/1

Y1 - 2010/9/1

N2 - We earlier reported a significant association between the cytochrome P450 2D6 (CYP2D6) genotype and the clinical outcome in 282 Japanese breast cancer patients receiving tamoxifen monotherapy. Although many research groups have provided evidence indicating the CYP2D6 genotype as one of the strongest predictors of tamoxifen response, the results still remain controversial. We hypothesized that concomitant treatment was one of the causes of these controversial results. We then studied 167 breast cancer patients who received tamoxifen-combined therapy to evaluate the effects of concomitant treatment on the association analysis and observed no significant association between CYP2D6 genotype and recurrence-free survival (P=0.44, hazard ratio: 0.64, 95% confidential interval: 0.20-1.99 in patients with two variant alleles vs. patients without a variant allele). When we carried out two subgroup analyses for nodal status and tumor size, we observed a positive association between the CYP2D6 genotype and the clinical outcome only in patients who received tamoxifen monotherapy. This study explained a part of the discrepancies among the reported results.

AB - We earlier reported a significant association between the cytochrome P450 2D6 (CYP2D6) genotype and the clinical outcome in 282 Japanese breast cancer patients receiving tamoxifen monotherapy. Although many research groups have provided evidence indicating the CYP2D6 genotype as one of the strongest predictors of tamoxifen response, the results still remain controversial. We hypothesized that concomitant treatment was one of the causes of these controversial results. We then studied 167 breast cancer patients who received tamoxifen-combined therapy to evaluate the effects of concomitant treatment on the association analysis and observed no significant association between CYP2D6 genotype and recurrence-free survival (P=0.44, hazard ratio: 0.64, 95% confidential interval: 0.20-1.99 in patients with two variant alleles vs. patients without a variant allele). When we carried out two subgroup analyses for nodal status and tumor size, we observed a positive association between the CYP2D6 genotype and the clinical outcome only in patients who received tamoxifen monotherapy. This study explained a part of the discrepancies among the reported results.

UR - http://www.scopus.com/inward/record.url?scp=77955924464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955924464&partnerID=8YFLogxK

U2 - 10.1097/FPC.0b013e32833af231

DO - 10.1097/FPC.0b013e32833af231

M3 - Article

C2 - 20574415

AN - SCOPUS:77955924464

VL - 20

SP - 565

EP - 568

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

SN - 1744-6872

IS - 9

ER -